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PROPAFENONE COMPARED ldITH AMIODARONE FOR CONVERSION OF 
PAROXYSMAL ATRIAL FIBRILLATION TO SINUS RHYTHM 
Giuseppe Gibelli, Carlo De Ponti. Cernusco 
Hospital, Depkment of Cardiology, Milan, Italy. 
The effectiveness of propafenone versus amiodarone was 
compared for conversion of paroxysmal atria1 fibt,i]]ation 
to sinus rhythm in an open parallel group study. 
Forty consecutive adult pataents with atrial fibril- 
lation less than 7 days" duration, without clinical 
evidence of heart failure, were randomized to treatment 
with propafenone (group ?,n=20) or amiodarone (group 2, 
n=20). 0here was no difference in left atrial size (echo- 
determined) between the two groups. Intravenous propafe- 
none was given as a 2 mg/kg bolus over 10 min followed by 
a 10 mg/kg infusion for 24 hours. Amiodarone was given 
as a 5 mg/kg intravenous bolus over 10 min fo 
15 mg/kg infusion for 24 hours. 
Two patients in each group ccnwerted spontaneously 
before treatment. In the remaining patients, sinus rhythm 
was restored within 24 hours in 16 patients of group 1 
(89%) and 14 patients of group 2 (76%). The median tire 
to conversion was 1.7 hour; in group 1 and 10 hours in 
roup 2 (p less than 0.05). No serious adverse effects 
ere noted in either group. 
In conclusion, propafenone as as zffective and safe 
as amiodarone and it acted significantly faster in 
promoting conversi 
to sinus rhythm. 
on of paroxysma 1 atria1 fibrillation 
University of Arizona, Tucson, Arizona 
While controversy regarding the efficacy and even safety of 
digoxin (D) in chronic congestive heart failure persists. guidelines 
for itssafe and effective use are known. To examine the current 
clinical use of D, we retrospectively examined 326 adult patients 
referred for cardiac transplantation with ischemic or non-ischemic 
dilated cardiomyopathy, LVEF ~40% (64% with LVEF ~25%). D 
was being used by 236/326 pts (72%) with a mean dose of 0.23 
mg/day. 
n 6 
LVEF (mean %) 17.5 19.7 
Cardiac Index(mean) 2.5 2.5 
?(mean) 22.5 21.1 
mean) 48 6 50 4 
mic etiology 53% 67% <3.001 
Trough levels of D were obtained in 136/236 pts(58%) wtth a mean 
of 1 .O rig/ml (range O-3.7 rig/ml). In these pts, 38% had a lewel 
e 0.6 rig/ml, while 54% had levels between 0.8 8 1.8 rig/ml. Levels 
~1.8 nglml were seen in 8% of pts. 
We conclude that while there is no apparent selection by 
ventricular function for pts given D, it is inadequately prescribed or 
monitored in nearly l/2 of those pts with severe IeR ventricular 
dysfunction most likely to benefit. The optimal clinical effect of 
digitalis, as well as potential adverse consequences, have 
probably been underestimated & must be weighed in its clinical 
use as well as in future studies of its safety and efficacy. 
chael Kupp,GJn&r Giesen, Hospital 
St. taisrtirl, ~blenz, Germany 
ynamic effects of acute and chrtic! trea~twitl-l 
vascdilators WDI k82re assessed in ~tients witi 
chronic heaPc failure of NYI-R=+class III-Iv.Ch& of 24 
prazosin: contzrol 
CI ; 2.44+0.06 2.91+0.13 3.069.14 3.65+0.14 2.72zO.20 3.3620.3'1 3.81zO.38 4.41~0.40 
P 26.2+3,8 21.3+1.8 20.3+1.0 20.3+1.7 29.3T5.6 32.8%.8 32.5;S.a 37.5'58.5 
bmnIiGP ,SK6i.rt) pEBnd)o?? 3 booths 
reversal of tke effects on PFP a 
with PRA may be-atleast in par+ - 
regulation of al*-1-adrenoceptors.This seems to 
by the alpha-l-adrenoceptor agonist of the 
(-)-enantiomer of tk racemic m.ixture of (+/-I DOB. 
and Hendrik du T Theron, llniversity of South Alabama, 
